NCR2

NCR2 encodes NKp44, an activating natural cytotoxicity receptor on NK cells that integrates signals from diverse ligands—including the tumor-derived growth factor PDGF-DD, proliferating cell nuclear antigen (PCNA), and α2,3-sialylated N-glycans—to regulate cytokine secretion and cytotoxicity (PMID:29275861, PMID:29875773, PMID:22466566). Activating signals are transduced through noncovalent association with the ITAM-containing adaptor DAP12 via a critical transmembrane lysine (K183), while a cis-interaction with syndecan-4 on the NK cell surface constitutively dampens receptor triggering by modulating NKp44 membrane distribution (PMID:14707061, PMID:25546090). Alternative splicing generates functionally distinct isoforms: the ITIM-containing NKp44-1 variant mediates inhibitory signaling upon PCNA engagement, impairing lytic immune synapse formation, and the decidual cytokine microenvironment shifts splice variant expression to suppress cytotoxicity (PMID:27102296, PMID:26666685). The NKp44 ectodomain is sufficient to confer non-MHC-restricted tumor recognition when expressed as a chimeric antigen receptor on T cells (PMID:29085357).

1. 2004 High

   Establishing the signaling mechanism: it was unknown how NKp44 couples surface engagement to intracellular activation; mutagenesis showed that noncovalent association with DAP12 through transmembrane K183 is required for surface expression and activating signaling, while the cytoplasmic ITIM-like motif does not recruit inhibitory phosphatases.

   Evidence Chimeric receptor expression, K183 and Y238F site-directed mutagenesis, redirected cytotoxicity, co-IP, and pervanadate phosphorylation in NK-like cell lines

   PMID:14707061

   Open questions at the time

   • Whether additional adaptor proteins besides DAP12 contribute to NKp44 signaling
   • Structural basis of the NKp44–DAP12 transmembrane interaction
2. 2012 Medium

   Identifying a glycan ligand class: it was unknown what molecular structures on target cells NKp44 recognizes; recombinant domain binding and mutagenesis demonstrated that NKp44 engages multimeric α2,3-sialylated N-glycans through a positively charged patch (R47, R55, R92, R95, K103, R106) in its Ig-like ectodomain.

   Evidence Recombinant NKp44 binding to sialylated transferrin, competitive binding, and site-directed mutagenesis

   PMID:22466566

   Open questions at the time

   • Physiological glycoprotein carriers of these sialylated glycans on tumor or healthy cells
   • Whether glycan binding contributes to activating versus inhibitory outcome
   • Single-lab finding without independent replication
3. 2015 Medium

   Revealing cis-regulation and splice-variant-driven functional plasticity: it was unclear how NKp44 activity is tuned on the NK cell surface; two studies showed that (i) syndecan-4 interacts with NKp44 in cis to dampen receptor triggering, and (ii) decidual cytokines shift NCR2 splice variant expression to reduce cytotoxicity, linking microenvironment to receptor isoform balance.

   Evidence Co-IP and confocal microscopy of NKp44–SDC4 cis-interaction with heparan sulfate disruption; RT-PCR splice profiling of dNK vs. pNK cells with cytokine conversion assays

   PMID:25546090 PMID:26666685

   Open questions at the time

   • Molecular basis of how syndecan-4 modulates NKp44 membrane distribution
   • Signaling pathways downstream of decidual cytokines that regulate splicing
   • Whether cis-regulation and splice variant balance interact mechanistically
4. 2016 Medium

   Defining the inhibitory isoform mechanism: it was known that NKp44 has an ITIM-like motif but the 2004 study found no inhibitory function; isoform-specific analysis showed that the NKp44-1 (ITIM-containing) splice variant specifically mediates inhibitory signaling upon PCNA engagement, impairing stable lytic immune synapse formation.

   Evidence Splice variant transfection in NK-92 cells, immune synapse formation assay with PCNA-overexpressing targets, cytotoxicity assays

   PMID:27102296

   Open questions at the time

   • Identity of the phosphatase recruited by the NKp44-1 ITIM
   • Whether NKp44-1 inhibitory signaling is relevant for ligands other than PCNA
   • Single-lab finding
5. 2017 High

   Identifying PDGF-DD as a tumor-derived protein ligand: prior ligand identification was limited to glycans and PCNA; a secretome screen identified PDGF-DD as a direct NKp44 ligand whose engagement triggers IFN-γ and TNF-α secretion, inducing tumor cell growth arrest in vitro and suppressing tumor dissemination in vivo.

   Evidence Secretome library screen, direct binding assay, NK cell cytokine secretion assays, in vivo mouse tumor dissemination model

   PMID:29275861

   Open questions at the time

   • Whether PDGF-DD and sialylated glycans compete for the same or distinct NKp44 binding sites
   • Contribution of PDGF-DD engagement to NKp44-mediated cytotoxicity versus cytokine-only responses
6. 2018 Medium

   Mapping the PCNA-binding site and demonstrating therapeutic exploitation: the precise NKp44 region mediating PCNA recognition was unknown; peptide mapping identified a linear binding determinant (pep8) on NKp44, and cell-penetrating peptide fusions targeting intracellular PCNA suppressed tumor growth in vivo.

   Evidence Competitive binding assays, peptide–PCNA interaction mapping, cell viability assays, in vivo 4T1 and B16 tumor models

   PMID:29875773

   Open questions at the time

   • Whether pep8-based anti-tumor activity operates through the NKp44–PCNA immune axis or solely through direct PCNA disruption
   • Structural characterization of the NKp44–PCNA interface
   • Single-lab findings

• The structural basis of ligand selectivity (PDGF-DD vs. PCNA vs. sialylated glycans), how signals from activating (DAP12) and inhibitory (NKp44-1 ITIM) isoforms are integrated at the immune synapse, and the in vivo relevance of cis-regulation by syndecan-4 remain unresolved.
• No co-crystal or cryo-EM structure of NKp44 with any ligand
• Quantitative contribution of each isoform in mixed splice-variant NK cell populations in vivo
• Whether NKp44 signals alone or in obligate co-stimulation with other NCRs in physiological settings